To directly assess the role of GABA-T in obesity-induced metabolic dysfunction, we treated high-fat-diet (HFD)-induced obese mice with one of two irreversible GABA-T inhibitors, ethanolamine-O-sulfate (EOS) or vigabatrin (8 mg/day intraperitoneally [i.p.]) or phosphate-buffered saline vehicle. This evidence concerns the gene ABAT and obesity due to melanocortin 4 receptor deficiency.